Enhanced levels of costimulation lead to reduced effector/memory CD8 + T cell functionality

Journal of Immunology

Volumn 179, Issue 6, 2007, Pages 3524-3534

  Mostböck, Sven ^a   Vidal, Silvia ^b   Schlom, Jeffrey ^a   Sabzevari, Helen ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Sant Pau University Hospital   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B; INTERCELLULAR ADHESION MOLECULE 1; NUCLEOPORIN 98; PROTEIN KINASE ZAP 70; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR; CORE PROTEIN; EPITOPE; GRANZYME; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; NP PROTEIN, INFLUENZA A VIRUS; NUCLEOPROTEIN; PEPTIDE FRAGMENT; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL FUNCTION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; ENZYME REGULATION; IMMUNE RESPONSE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; AMINO ACID SUBSTITUTION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; COMPARATIVE STUDY; CYTOLOGY; CYTOTOXICITY; DOSE RESPONSE; DOWN REGULATION; DRUG ANTAGONISM; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; SYNTHESIS; TRANSGENIC MOUSE; UPREGULATION;

AMINO ACID SUBSTITUTION; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOWN-REGULATION; GRANZYMES; IMMUNODOMINANT EPITOPES; IMMUNOLOGIC MEMORY; LIGANDS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NUCLEOPROTEINS; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL; RNA-BINDING PROTEINS; UP-REGULATION; VIRAL CORE PROTEINS;

EID: 35748961707     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.6.3524     Document Type: Article

References (64)

1. van der Burg, S. H., M. J. Visseren, R. M. Brandt, W. M. Kast, and C. J. Melief. 1996. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156: 3308-3314.
2. + T cells. J. Immunol. 170: 1822-1829.
3. Kerry, S. E., J. Buslepp, L. A. Cramer, R. Maile, L. L. Hensley, A. I. Nielsen, P. Kavathas, B. J. Vilen, E. J. Collins, and J. A. Frelinger. 2003. Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement. J. Immunol. 171: 4493-4503.
4. Kim, D. T., J. B. Rothbard, D. D. Bloom, and C. G. Fathman. 1996. Quantitative analysis of T cell activation: role of TCR/ligand density and TCR affinity. J. Immunol. 156: 2737-2742.
5. Slansky, J. E., F. M. Rattis, L. F. Boyd, T. Fahmy, E. M. Jaffee, J. P. Schneck, D. H. Margulies, and D. M. Pardoll. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13: 529-538.
6. Heath, W. R., and F. R. Carbone. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19: 47-64.
7. Legge, K. L., R. K. Gregg, R. Maldonado-Lopez, L. Li, J. C. Caprio, M. Moser, and H. Zaghouani. 2002. On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J. Exp. Med. 196: 217-227.
8. Melief, C. J. 2003. Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur. J. Immunol. 33: 2645-2654.
9. Storni, T., and M. F. Bachmann. 2003. On the role of APC-activation for in vitro versus in vivo T cell priming. Cell. Immunol. 225: 1-11.
10. Chambers, C. A. 2001. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol. 22: 217-223.
11. Bachmann, M. F., E. Sebzda, T. M. Kundig, A. Shahinian, D. E. Speiser, T. W. Mak, and P. S. Ohashi. 1996. T cell responses are governed by avidity and co-stimulatory thresholds. Eur. J. Immunol. 26: 2017-2022.
12. Sprent, J., and C. D. Surh. 2002. T cell memory. Annu. Rev. Immunol. 20: 551-579.
13. Yu, X. Z., P. J. Martin, and C. Anasetti. 2003. CD28 signal enhances apoptosis of CD8 T cells after strong TCR ligation. J. Immunol. 170: 3002-3006.
14. Anderton, S. M., and D. C. Wraith. 2002. Selection and fine-tuning of the autoimmune T-cell repertoire. Nat. Rev. Immunol. 2: 487-498.
15. Alexander-Miller, M. A., G. R. Leggatt, A. Sarin, and J. A. Berzofsky. 1996. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184: 485-492.
16. Sloan-Lancaster, J., B. D. Evavold, and P. M. Allen. 1994. Th2 cell clonal anergy as a consequence of partial activation. J. Exp. Med. 180: 1195-1205.
17. Ausubel, L. J., J. I. Krieger, and D. A. Hafler. 1997. Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99. J. Immunol. 159: 2502-2512.
18. Evavold, B. D., and P. M. Allen. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 252: 1308-1310.
19. Faith, A., C. A. Akdis, M. Akdis, A. Joss, D. Wymann, and K. Blaser. 1999. An altered peptide ligand specifically inhibits Th2 cytokine synthesis by abrogating TCR signaling. J. Immunol. 162: 1836-1842.
20. Jameson, S. C., and M. J. Bevan. 1995. T cell receptor antagonists and partial agonists. Immunity 2: 1-11.
21. + T cells induced by low avidity engagement of T cell receptor. J. Exp. Med. 194: 719-731.
22. Rogers, P. R., H. M. Grey, and M. Croft. 1998. Modulation of naive CD4 T cell activation with altered peptide ligands: the nature of the peptide and presentation in the context of costimulation are critical for a sustained response. J. Immunol. 160: 3698-3704.
23. Rogers, P. R., and M. Croft. 1999. Peptide dose, affinity, and time of differentiation can contribute to the Th1/Th2 cytokine balance. J. Immunol. 163: 1205-1213.
24. Zivny, J., M. DeFronzo, W. Jarry, J. Jameson, J. Cruz, F. A. Ennis, and A. L. Rothman. 1999. Partial agonist effect influences the CTL response to a heterologous dengue virus serotype. J. Immunol. 163: 2754-2760.
25. Auphan-Anezin, N., G. Verdeil, and A. M. Schmitt-Verhulst. 2003. Distinct thresholds for CD8 T cell activation lead to functional heterogeneity: CD8 T cell priming can occur independently of cell division. J. Immunol. 170: 2442-2448.
26. + T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Cancer Res. 63: 1560-1567.
27. de Visser, K. E., T. A. Cordaro, H. W. Kessels, F. H. Tirion, T. N. Schumacher, and A. M. Kruisbeek. 2001. Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands. J. Immunol. 167: 3818-3828.
28. Dressel, A., J. L. Chin, A. Sette, R. Gausling, P. Hollsberg, and D. A. Hafler. 1997. Autoantigen recognition by human CD8 T cell clones: enhanced agonist response induced by altered peptide ligands. J. Immunol. 159: 4943-4951.
29. Hartemann-Heurtier, A., L. T. Mars, N. Bercovici, S. Desbois, C. Cambouris, E. Piaggio, J. Zappulla, A. Saoudi, and R. S. Liblau. 2004. An altered self-peptide with superagonist activity blocks a CD8-mediated mouse model of type 1 diabetes. J. Immunol. 172: 915-922.
30. Hollsberg, P., W. E. Weber, F. Dangond, V. Batra, A. Sette, and D. A. Hafler. 1995. Differential activation of proliferation and cytotoxicity in human T-cell lymphotropic virus type I Tax-specific CD8 T cells by an altered peptide ligand. Proc. Natl. Acad. Sci. USA 92: 4036-4040.
31. + T cell function. J. Exp. Med. 198: 99-109.
32. Martin, S., H. Kohler, H. U. Weltzien, and C. Leipner. 1996. Selective activation of CD8 T cell effector functions by epitope variants of lymphocytic choriomeningitis virus glycoprotein. J. Immunol. 157: 2358-2365.
33. + hapten-specific cytotoxic T-cell clone by an altered hapten-peptide ligand. Immunology 102: 8-14.
34. Shotton, D. M., and A. Attaran. 1998. Variant antigenic peptide promotes cytotoxic T lymphocyte adhesion to target cells without cytotoxicity. Proc. Natl. Acad. Sci. USA 95: 15571-15576.
35. Hodge, J. W., K. Y. Tsang, D. J. Poole, and J. Schlom. 2003. General keynote: vaccine strategies for the therapy of ovarian cancer. Gynecol. Oncol. 88: S97-S104; discussion S110-S103.
36. Townsend, A. R., J. Rothbard, F. M. Gotch, G. Bahadur, D. Wraith, and A. J. McMichael. 1986. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44: 959-968.
37. Mamalaki, C., J. Elliott, T. Norton, N. Yannoutsos, A. R. Townsend, P. Chandler, E. Simpson, and D. Kioussis. 1993. Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen. Dev. Immunol. 3: 159-174.
38. Tourdot, S., M. Oukka, J. C. Manuguerra, V. Magafa, I. Vergnon, N. Riche, M. Bruley-Rosset, P. Cordopatis, and K. Kosmatopoulos. 1997. Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination. J. Immunol. 159: 2391-2398.
39. Smyth, L. A., O. Williams, R. D. Huby, T. Norton, O. Acuto, S. C. Ley, and D. Kioussis. 1998. Altered peptide ligands induce quantitatively but not qualitatively different intracellular signals in primary thymocytes. Proc. Natl. Acad. Sci. USA 95: 8193-8198.
40. + cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther. 11: 665-680.
41. Hodge, J. W., H. Sabzevari, A. G. Yafal, L. Gritz, M. G. Lorenz, and J. Schlom. 1999. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59: 5800-5807.
42. McKinstry, K. K., T. Strutt, A. Buck, and S. L. Swain. 2007. Functional analysis of protective influenza-specific memory CD4 T cell responses. In Keystone Symposia-Immunologic Memory 2007 Abstract Book. Santa Fe, p. 82.
43. + T cell effectors can become memory cells with high efficiency and without further division. Nat. Immunol. 2: 705-710.
44. + T cells in protective immunity to influenza. Immunol. Rev. 211: 8-22.
45. Hodge, J. W., A. N. Rad, D. W. Grosenbach, H. Sabzevari, A. G. Yafal, L. Gritz, and J. Schlom. 2000. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J. Natl. Cancer Inst. 92: 1228-1239.
46. Dutton, R. W., L. M. Bradley, and S. L. Swain. 1998. T cell memory. Annu. Rev. Immunol. 16: 201-223.
47. + T cells into Th1 and Th2 subsets. J. Immunol. 159: 5802-5809.
48. + T cells in response to antagonist ligands. J. Exp. Med. 184: 149-157.
49. Zhao, Q., and A. Weiss. 1996. Enhancement of lymphocyte responsiveness by a gain-of-function mutation of ZAP-70. Mol. Cell. Biol. 16: 6765-6774.
50. Wei, S., A. M. Gamero, J. H. Liu, A. A. Daulton, N. I. Valkov, J. A. Trapani, A. C. Larner, M. J. Weber, and J. Y. Djeu. 1998. Control of lytic function by mitogen-activated protein kinase/extracellular regulatory kinase 2 (ERK2) in a human natural killer cell line: identification of perforin and granzyme B mobilization by functional ERK2. J. Exp. Med. 187: 1753-1765.
51. Jiang, K., B. Zhong, D. L. Gilvary, B. C. Corliss, E. Hong-Geller, S. Wei, and J. Y. Djeu. 2000. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat. Immunol. 1: 419-425.
52. Costello, P. S., A. E. Walters, P. J. Mee, M. Turner, L. F. Reynolds, A. Prisco, N. Sarner, R. Zamoyska, and V. L. Tybulewicz. 1999. The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-κB pathways. Proc. Natl. Acad. Sci. USA 96: 3035-3040.
53. Villalba, M., J. Hernandez, M. Deckert, Y. Tanaka, and A. Altman. 2000. Vav modulation of the Ras/MEK/ERK signaling pathway plays a role in NFAT activation and CD69 up-regulation. Eur. J. Immunol. 30: 1587-1596.
54. Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188: 2205-2213.
55. Bernard, A., Lamy, and I. Alberti. 2002. The two-signal model of T-cell activation after 30 years. Transplantation 73: S31-35.
56. Stefanova, I., J. R. Dorfman, and R. N. Germain. 2002. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 420: 429-434.
57. + T cell survival is not directly linked to self-MHC-induced TCR signaling. Nat. Immunol. 1: 329-335.
58. + T cell survival. Adv. Exp. Med. Biol. 512: 97-105.
59. Kieper, W. C., J. T. Burghardt, and C. D. Surh. 2004. A role for TCR affinity in regulating naive T cell homeostasis. J. Immunol. 172: 40-44.
60. Saibil, S. D., T. Ohteki, F. M. White, M. Luscher, A. Zakarian, A. Elford, J. Shabanowitz, H. Nishina, P. Hugo, J. Penninger, et al. 2003. Weak agonist self-peptides promote selection and tuning of virus-specific T cells. Eur. J. Immunol. 33: 685-696.
61. Rogers, P. R., C. Dubey, and S. L. Swain. 2000. Qualitative changes accompany memory T cell generation: faster, more effective responses at lower doses of antigen. J. Immunol. 164: 2338-2346.
62. Kissler, S., S. M. Anderton, and D. C. Wraith. 2002. Cross-reactivity and T-cell receptor antagonism of myelin basic protein-reactive T cells is modulated by the activation state of the antigen presenting cell. J. Autoimmun. 19: 183-193.
63. Quaratino, S., L. P. Duddy, and M. Londei. 2000. Fully competent dendritic cells as inducers of T cell anergy in autoimmunity. Proc. Natl. Acad. Sci. USA 97: 10911-10916.
64. Marshall, J. L., J. L. Gulley, P. M. Arlen, P. K. Beetham, K. Y. Tsang, R. Slack, J. W. Hodge, S. Doren, D. W. Grosenbach, J. Hwang, et al. 2005. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte- macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 23: 720-731.